Incyte grabs control of a cancer drug from Calithera’s pipeline for $53M up front
Incyte $INCY has swooped in and gained control of Calithera’s $CALA number #2 cancer drug with a $53 million cash payday.
The collaboration gives Incyte the lead on CB-1158, a therapy designed to inhibit arginase, an enzyme that reins in T-cell and natural killer cell activation in tumors. The plan is to test it as a monotherapy but also in combination with immuno-oncology drugs – in particular an anti-PD-1 therapy – to test its potential for future combos.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.